Clinical trials
Phase 1 Carcinoma, Intraductal, Noninfiltrating trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
25 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2005 | 3 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 1 |
| 2010 | 3 |
| 2013 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 1 |
| 2022 | 2 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 13 |
| Active, not recruiting | 3 |
| Recruiting | 3 |
| Withdrawn | 3 |
| Terminated | 2 |
| Suspended | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 5 |
| Abramson Cancer Center at Penn Medicine | 1 |
| Avelas Biosciences, Inc. | 1 |
| City of Hope Medical Center | 1 |
| Columbia University | 1 |
| Finn, Olivera, PhD | 1 |
| Laura Esserman | 1 |
| Mark Dewhirst | 1 |
| Masonic Cancer Center, University of Minnesota | 1 |
| Mayo Clinic | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Carcinoma, Intraductal, Noninfiltrating | 25 |
| Breast Neoplasms | 17 |
| Breast Carcinoma In Situ | 11 |
| Carcinoma, Ductal, Breast | 3 |
| Carcinoma, Lobular | 2 |
| Breast Diseases | 1 |
| Fibroadenoma | 1 |
| Triple Negative Breast Neoplasms | 1 |
Trials
Showing 51 to 25 of 25. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.